Latest / DDReg Knowledge Capsule / Global Regulatory Operating Model For Pharma Leaders

Transcript

Global Regulatory Operating Model For Pharma Leaders · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Imagine spending a billion dollars and like 10 years developing
• 0:04
  Speaker 1: a lifesaving drug only to have it blocked from entering
• 0:08
  Speaker 1: a country because someone misread a local, unwritten bureaucratic rule.
• 0:13
  Speaker 1: Welcome to D.D. Reg Knowledge Capsule.
• 0:15
  Speaker 2: Yeah, that happens a lot more often than people think.
• 0:17
  Speaker 1: Right. And, you know, there's this fascinating paradox in the
• 0:20
  Speaker 1: corporate world. You walk into a boardroom and someone draws
• 0:23
  Speaker 1: these perfect symmetrical boxes on a whiteboard. representing a global
• 0:29
  Speaker 1: organizational chart.
• 0:30
  Speaker 2: Oh, the classic whiteboard org chart.
• 0:32
  Speaker 1: Exactly. It looks incredibly robust. It makes perfect logical sense
• 0:35
  Speaker 1: on paper. But then, you know, you take that beautiful
• 0:39
  Speaker 1: whiteboard design, you deploy it into the real world, and
• 0:41
  Speaker 1: it completely falls apart.
• 0:42
  Speaker 2: It shatters on impact. I mean, reality, especially when you're
• 0:45
  Speaker 2: dealing with multiple sovereign countries, it just refuses to fit
• 0:49
  Speaker 2: into those neat little whiteboard boxes.
• 0:51
  Speaker 1: Yeah, because the real world is messy.
• 0:53
  Speaker 2: It is incredibly messy. It's full of friction. And driven
• 0:56
  Speaker 2: by human nuances that an org chart simply cannot capture.
• 0:59
  Speaker 1: And nowhere is that friction more expensive or, honestly, more
• 1:05
  Speaker 1: obvious than in the world of global pharmaceuticals. So today,
• 1:09
  Speaker 1: the mission of our deep dive is to explore exactly
• 1:12
  Speaker 1: how pharmaceutical companies can effectively structure their regulatory operations across
• 1:17
  Speaker 1: the globe.
• 1:18
  Speaker 2: Which is such a massive challenge right now.
• 1:20
  Speaker 1: It really is. And our source material for this is
• 1:23
  Speaker 1: a comprehensive, just incredibly detailed guide on the global regulatory
• 1:28
  Speaker 1: operating model. It was published by D-Drate Pharma in September 2026.
• 1:33
  Speaker 2: It's a really vital read for the industry because getting
• 1:36
  Speaker 2: a new medicine approved, you know, it isn't just about
• 1:38
  Speaker 2: having good science anymore.
• 1:40
  Speaker 1: Right. The science is just the baseline.
• 1:41
  Speaker 2: Exactly. It is about navigating the staggering bureaucratic labyrinth that
• 1:46
  Speaker 2: literally changes the moment you cross a border.
• 1:48
  Speaker 1: So whether you are a life sciences professional prepping for
• 1:51
  Speaker 1: a major organizational strategy meeting or you are just someone
• 1:54
  Speaker 1: who is insanely curious about how the complex machinery behind
• 1:57
  Speaker 1: global medicine actually works, you're going to want to stick around. Oh, absolutely.
• 2:01
  Speaker 1: We are going to unpack... Why these systems fail and
• 2:05
  Speaker 1: how to fix them. And I think it all starts
• 2:08
  Speaker 1: with that whiteboard paradox we mentioned. Why do these organizational
• 2:12
  Speaker 1: models fail so often? Well, as our source points out,
• 2:16
  Speaker 1: it's because pharma regulation remains stubbornly jurisdiction specific. Right.
• 2:21
  Speaker 2: And that tension is the core of the whole problem.
• 2:23
  Speaker 2: There is no universally prescribed, you know, one size fits
• 2:27
  Speaker 2: all organizational model that works for every single pharma company.
• 2:30
  Speaker 1: But looking at the data, we sort of know what
• 2:32
  Speaker 1: definitely does not work.
• 2:34
  Speaker 2: We do. Organizations usually fail when they swing too far
• 2:37
  Speaker 2: toward one of two extremes. So that's excessive sexualization or
• 2:40
  Speaker 2: excessive decentralization.
• 2:42
  Speaker 1: OK, let's unpack this, starting with excessive centralization. This is
• 2:45
  Speaker 1: the classic headquarters knows best approach. Yep.
• 2:48
  Speaker 2: Everything is controlled from a single glass tower in New
• 2:51
  Speaker 2: York or Geneva.
• 2:52
  Speaker 1: Which sounds incredibly efficient in theory.
• 2:54
  Speaker 2: In theory, sure. But in practice, it severely weakens a
• 2:58
  Speaker 2: company's sensitivity to local realities. I mean, if a global
• 3:01
  Speaker 2: team tries to micromanage every submission, they miss jurisdiction-specific regulatory expectations.
• 3:07
  Speaker 1: Because they're just too far removed from the actual market.
• 3:10
  Speaker 2: Exactly. They end up ignoring local authority precedents, and they
• 3:14
  Speaker 2: completely misunderstand the procedural requirements on the ground.
• 3:18
  Speaker 1: So a strategy that looks brilliant at global headquarters might
• 3:21
  Speaker 1: hit a brick wall in Tokyo, simply because the central
• 3:25
  Speaker 1: team didn't know about a specific like unwritten expectation of
• 3:29
  Speaker 1: the Japanese health authority.
• 3:30
  Speaker 2: Yeah, that happens all the time. But then you look
• 3:32
  Speaker 2: at the other extreme, excessive decentralization, and that has its
• 3:37
  Speaker 2: own massive pitfalls.
• 3:38
  Speaker 1: It always makes me think of managing a global restaurant chain.
• 3:42
  Speaker 1: I mean, if headquarters forces the exact same menu everywhere,
• 3:45
  Speaker 1: it bombs in local markets because tastes differ.
• 3:47
  Speaker 2: Right, you need local flavors.
• 3:49
  Speaker 1: But if every single franchise invents its own recipes from scratch, well,
• 3:53
  Speaker 1: it's no longer the same restaurant chain. You've just got chaos.
• 3:56
  Speaker 2: Chaos is the perfect word for it. When a pharma
• 3:58
  Speaker 2: company is too decentralized, the regulatory governance completely fragments.
• 4:04
  Speaker 1: And the source details how this leads to incredibly wasteful
• 4:08
  Speaker 1: duplicated activities, right?
• 4:09
  Speaker 2: It's wild. You could literally have teams in 10 different
• 4:14
  Speaker 2: countries doing the exact same research, writing the same justifications,
• 4:19
  Speaker 2: just to answer the exact same question from 10 different regulators.
• 4:23
  Speaker 1: Wow. And it's not just wasteful, it's dangerous.
• 4:27
  Speaker 2: Oh, absolutely.
• 4:28
  Speaker 1: Because if everyone is doing their own thing, you end
• 4:30
  Speaker 1: up with inconsistent positions. You might have a local team
• 4:34
  Speaker 1: in one country interpreting clinical safety data, one way to
• 4:38
  Speaker 1: appease their regulator, and another team next door interpreting the
• 4:41
  Speaker 1: exact same scientific evidence differently.
• 4:43
  Speaker 2: Which is a massive compliance risk.
• 4:45
  Speaker 1: But wait, I have to push back here for a second.
• 4:47
  Speaker 2: Okay, go ahead.
• 4:48
  Speaker 1: Hasn't the ICH, the International Council for Harmonization and Standard CTDs,
• 4:53
  Speaker 1: made this a lot easier? I mean, we have electronic
• 4:57
  Speaker 1: common technical documents now.
• 4:58
  Speaker 2: We do, yeah.
• 4:59
  Speaker 1: So if the files are all standardized globally, why can't
• 5:02
  Speaker 1: we just have one central team handling everything remotely?
• 5:05
  Speaker 2: Well, what's fascinating here is that that's a very common misconception.
• 5:08
  Speaker 2: While we do have fantastic standards now, we do not
• 5:10
  Speaker 2: have a single worldwide medicines regulator.
• 5:13
  Speaker 1: Right, there's no global FDA.
• 5:15
  Speaker 2: Exactly. The ICH has harmonized the science and the technical formatting, sure.
• 5:20
  Speaker 2: But even with the highly advanced ECTD version 4.0, you
• 5:24
  Speaker 2: are combining a harmonized technical standard with regional Module 1 requirements.
• 5:29
  Speaker 1: Module 1 being the administrative, highly specific local information.
• 5:33
  Speaker 2: Exactly that. The ICH explicitly states that its ECTD v4. 0
• 5:39
  Speaker 2: implementation package must be used alongside regional requirements.
• 5:43
  Speaker 1: Oh, so you can't just bypass the local rules.
• 5:44
  Speaker 2: No. Implementation still happens according to national or regional procedures.
• 5:48
  Speaker 2: You cannot just click a button and submit a universal
• 5:50
  Speaker 2: global dossier.
• 5:51
  Speaker 1: So the objective cannot be total centralization or total localization.
• 5:55
  Speaker 2: No. The sweet spot is what the source calls controlled decentralization.
• 6:00
  Speaker 1: Controlled decentralization. Meaning you enforce global consistency where consistency creates value,
• 6:06
  Speaker 1: but you mandate local ownership where local knowledge actually matters.
• 6:10
  Speaker 2: Exactly. You have to balance the two.
• 6:12
  Speaker 1: So if we can't be completely centralized or totally local,
• 6:16
  Speaker 1: how do you actually bridge that gap without overwhelming headquarters?
• 6:22
  Speaker 1: Let's talk about where the global strategy actually lives and
• 6:25
  Speaker 1: how it trickles down through these different layers.
• 6:27
  Speaker 2: Right. So let's look at layers one and two, the
• 6:29
  Speaker 2: global level. The overarching principle here is that global regulatory
• 6:33
  Speaker 2: affairs shouldn't be attempting to replace local judgment. That is
• 6:37
  Speaker 2: a fool's errand.
• 6:38
  Speaker 1: That's just impossible. It is.
• 6:40
  Speaker 2: Instead, their job is to govern the scientific core of
• 6:42
  Speaker 2: the product to ensure portfolio consistency worldwide.
• 6:46
  Speaker 1: OK, so what specifically do they own in this model?
• 6:50
  Speaker 2: The global team owns the big picture target indications, the
• 6:53
  Speaker 2: pivotal evidence package, the major health authority engagement strategy and
• 6:57
  Speaker 2: core labeling positions.
• 6:59
  Speaker 1: They are establishing the absolute scientific truth of the drug
• 7:02
  Speaker 1: that needs to be defended across all markets.
• 7:04
  Speaker 2: Yes. They ensure that the core clinical, non-clinical, and manufacturing
• 7:08
  Speaker 2: data is aligned everywhere. But they also own cross-market risk decisions,
• 7:12
  Speaker 2: which is crucial.
• 7:13
  Speaker 1: How does that work in practice?
• 7:14
  Speaker 2: Well, if a health authority in one country raises a
• 7:18
  Speaker 2: significant objection... Or if there is an emerging safety issue,
• 7:22
  Speaker 2: that isn't just a local problem anymore. That could affect
• 7:24
  Speaker 2: 10 other markets.
• 7:25
  Speaker 1: Ah, it's the ripple effect.
• 7:27
  Speaker 2: Exactly. You can't have a local affiliate making a panicked
• 7:30
  Speaker 2: commitment to a regulator in one country that accidentally backs
• 7:33
  Speaker 2: the global company into a corner everywhere else.
• 7:36
  Speaker 1: So global sets that core strategy. But dropping a global
• 7:40
  Speaker 1: mandate straight into a local market is a recipe for disaster,
• 7:44
  Speaker 1: which brings us to the necessity of layer three, Regional translation. Right.
• 7:49
  Speaker 2: The regional layer.
• 7:50
  Speaker 1: Which covers geographic clusters like the European Union, the Asia-Pacific
• 7:53
  Speaker 1: region or Latin America. But to play devil's advocate here,
• 7:57
  Speaker 1: doesn't a regional team just add a layer of middle
• 7:59
  Speaker 1: management bloat?
• 8:00
  Speaker 2: A lot of executives think that.
• 8:02
  Speaker 1: Right. Like why can't global just talk to local directly?
• 8:05
  Speaker 2: It's a fair question. And it's often the layer that
• 8:08
  Speaker 2: gets cut to save money. But regional teams are incredibly
• 8:11
  Speaker 2: valuable for efficiency and risk mitigation. Let's look at the
• 8:15
  Speaker 2: European Union example from the text.
• 8:16
  Speaker 1: Okay. Europe is always complicated.
• 8:19
  Speaker 2: Very. A regulatory strategy in the EU might involve centralized, decentralized,
• 8:24
  Speaker 2: or mutual recognition pathways.
• 8:27
  Speaker 1: Which are entirely different beasts. Centralized meaning one approval for
• 8:31
  Speaker 1: all of Europe, whereas mutual recognition means one country approves
• 8:34
  Speaker 1: it and you try to get the others to recognize
• 8:36
  Speaker 1: that approval.
• 8:37
  Speaker 2: Precisely. Those are highly tactical, highly specific procedures that simply
• 8:42
  Speaker 2: cannot be inferred from a U.S.-centric global strategy.
• 8:45
  Speaker 1: Right. A global team sitting in New Jersey isn't going
• 8:48
  Speaker 1: to know the nuances of navigating a mutual recognition procedure
• 8:52
  Speaker 1: across 15 European member states.
• 8:54
  Speaker 2: They just won't. And think about the sheer coordination of it.
• 8:57
  Speaker 2: If you have 10 clustered markets in a region that
• 8:59
  Speaker 2: have very similar requirements, the regional team establishes a common
• 9:03
  Speaker 2: interpretation of the global strategy.
• 9:05
  Speaker 1: So if you eliminate that regional hub.
• 9:07
  Speaker 2: You suddenly have 10 local affiliates all trying to solve
• 9:10
  Speaker 2: the exact same problem 10 different ways and firing off
• 9:13
  Speaker 2: 10 different urgent emails to the global team.
• 9:16
  Speaker 1: Oh, wow. Yeah, that sounds like a nightmare.
• 9:18
  Speaker 2: It is. Regional teams turn those isolated country-level observations into
• 9:23
  Speaker 2: broader patterns. They're the translators. They take the global scientific
• 9:28
  Speaker 2: mandate and figure out the most efficient procedural pathway for
• 9:31
  Speaker 2: their specific corner of the world.
• 9:33
  Speaker 1: Which brings us down to layer four. The literal boots
• 9:36
  Speaker 1: on the ground local execution.
• 9:38
  Speaker 2: Like front lines.
• 9:39
  Speaker 1: Yeah. And if you've ever worked in a matrix organization,
• 9:43
  Speaker 1: you know exactly what happens when decision rights aren't clear.
• 9:46
  Speaker 1: Emails go unanswered, blame gets passed around, and things just
• 9:50
  Speaker 1: grind to a halt.
• 9:51
  Speaker 2: And in pharma, that bureaucratic delay literally costs lives.
• 9:55
  Speaker 1: Exactly. I love this part of the source because it
• 9:57
  Speaker 1: completely shatters the myth that local regulations professionals are just
• 10:02
  Speaker 1: like submission factories, blindly uploading whatever PDFs Global sends them.
• 10:06
  Speaker 2: They are anything but submission factories. The local function is
• 10:10
  Speaker 2: the true intelligence node within this global network.
• 10:12
  Speaker 1: Because they're the ones actually talking to the regulators.
• 10:15
  Speaker 2: Right. They are sitting closest to the national legislation, the
• 10:17
  Speaker 2: shifting authority procedures. and most importantly, the actual human beings
• 10:22
  Speaker 2: at the local health agencies.
• 10:23
  Speaker 1: So the global team might know the drug best, but
• 10:27
  Speaker 1: the local team knows the regulator best.
• 10:29
  Speaker 2: I'd actually argue the local team's knowledge of the regulator
• 10:33
  Speaker 2: is what ultimately gets the drug over the finish line.
• 10:35
  Speaker 1: What specific things do they actually own, then?
• 10:38
  Speaker 2: Well, the local team owns the evolving authority expectations. They
• 10:43
  Speaker 2: manage national labeling adaptations. And they understand the informal submission
• 10:48
  Speaker 2: practices that you will never find written in an official
• 10:51
  Speaker 2: published guideline.
• 10:52
  Speaker 1: Oh, the unwritten rules.
• 10:53
  Speaker 2: Yes. And those can absolutely stall an application for months
• 10:58
  Speaker 2: if you ignore them. Local teams identify procedural bottlenecks before
• 11:02
  Speaker 2: they ever become obvious at the global level.
• 11:04
  Speaker 1: But a local regulatory lead isn't just staring at guidelines
• 11:07
  Speaker 1: all day, right? Here's where it gets really interesting. They
• 11:11
  Speaker 1: are basically diplomats dealing with every other department in the company.
• 11:15
  Speaker 2: But that cross-functional dance is so critical.
• 11:18
  Speaker 1: Because regulatory affairs doesn't exist in a vacuum. A global
• 11:21
  Speaker 1: model only works if decision rights are explicitly clear across
• 11:25
  Speaker 1: different company departments.
• 11:26
  Speaker 2: And this cross-functional web is where many supposedly robust operating
• 11:30
  Speaker 2: models stumble. They might perfectly define who is responsible for
• 11:34
  Speaker 2: what within the regulatory department, but they fail to define
• 11:38
  Speaker 2: how regulatory interacts with clinical or quality or supply chains.
• 11:43
  Speaker 1: Let's talk about the friction with manufacturing or CMC chemistry
• 11:47
  Speaker 1: manufacturing and controls. I would imagine this intersection is huge.
• 11:51
  Speaker 2: That's a massive pain point.
• 11:53
  Speaker 1: Like if a company decides to tweak a manufacturing process,
• 11:56
  Speaker 1: say changing a raw material supplier to save some money,
• 11:59
  Speaker 1: regulatory has to figure out if that requires a whole
• 12:02
  Speaker 1: new approval.
• 12:02
  Speaker 2: Exactly. Regulatory and CMC have to clarify up front who
• 12:06
  Speaker 2: owns the change assessments. Who determines if this tiny, seemingly
• 12:10
  Speaker 2: insignificant change in a manufacturing facility requires a major health
• 12:14
  Speaker 2: authority variation or if it's just a minor notification?
• 12:17
  Speaker 1: Because if those decision rights aren't clear, you risk manufacturing
• 12:21
  Speaker 1: a product you aren't legally allowed to sell.
• 12:23
  Speaker 2: Exactly.
• 12:24
  Speaker 1: And what about regulatory and clinical? Who owns the feedback
• 12:26
  Speaker 1: loop there?
• 12:27
  Speaker 2: Well, regulatory and clinical have to be perfectly aligned on
• 12:31
  Speaker 2: who owns authority feedback that might actually dictate how clinical
• 12:35
  Speaker 2: trials are run.
• 12:36
  Speaker 1: Ah, because the regulator might say, we don't like how
• 12:39
  Speaker 1: you're testing this.
• 12:40
  Speaker 2: Right. Regulatory owns the strategy of how to present the
• 12:43
  Speaker 2: protocol to the agency and how to negotiate the endpoints,
• 12:47
  Speaker 2: but they need clinical to actually execute the science behind it.
• 12:50
  Speaker 1: So if regulatory promises the agency a certain type of data,
• 12:54
  Speaker 1: clinical has to be able to actually deliver it.
• 12:56
  Speaker 2: Exactly. They have to be in lockstep. And the stakes
• 12:59
  Speaker 2: get even higher with pharmacovigilance or PV. Right.
• 13:03
  Speaker 1: The safety tracking. If a new side effect is discovered
• 13:06
  Speaker 1: out in the real world, regulatory and PV have to
• 13:09
  Speaker 1: coordinate on risk management plans and safety variations.
• 13:12
  Speaker 2: They do, and the clock is ticking the moment a
• 13:14
  Speaker 2: safety signal is validated. Who owns the communication to the authority?
• 13:19
  Speaker 2: Who ensures that the label is updated globally without causing
• 13:22
  Speaker 2: a massive panic?
• 13:24
  Speaker 1: It's so interconnected. But I think the most financially dangerous
• 13:27
  Speaker 1: intersection might actually be with the supply chain. Oh, definitely. Imagine.
• 13:31
  Speaker 1: Regulatory fails to tell supply chain that a manufacturing variation
• 13:35
  Speaker 1: isn't approved in Brazil yet. Supply chain, thinking everything is fine,
• 13:39
  Speaker 1: ships millions of dollars of the new product version to
• 13:41
  Speaker 1: Brazil and customs immediately seizes the entire shipment at the border.
• 13:46
  Speaker 2: It happens way more often than companies want to admit.
• 13:49
  Speaker 2: Supply chain needs to know the exact to the minute
• 13:52
  Speaker 2: approval status of a product so they know when it
• 13:54
  Speaker 2: can legally be manufactured, released, imported and distributed in each
• 13:59
  Speaker 2: specific market.
• 14:00
  Speaker 1: Okay, so we've mapped out this incredibly complex human element.
• 14:04
  Speaker 1: You've got global strategy, regional translators, local intelligence nodes, and
• 14:09
  Speaker 1: these massive cross-functional webs.
• 14:11
  Speaker 2: It's a lot of moving parts.
• 14:12
  Speaker 1: It is, which brings up a logistical nightmare. How do
• 14:15
  Speaker 1: thousands of people across all these different time zones and
• 14:18
  Speaker 1: departments actually communicate without dropping the ball constantly?
• 14:22
  Speaker 2: That is the pivotal question.
• 14:23
  Speaker 1: Because if we're relying on thousands of emails, this whole
• 14:25
  Speaker 1: thing collapses.
• 14:26
  Speaker 2: Oh, absolutely. And that's exactly why Regulatory infrastructure, which is
• 14:30
  Speaker 2: layer five, is undergoing such a massive evolution right now.
• 14:34
  Speaker 2: Regulatory operations can no longer just be an end stage
• 14:37
  Speaker 2: publishing team that sits in the basement, formats documents and
• 14:40
  Speaker 2: hits send.
• 14:41
  Speaker 1: Right. The days of just handing off a stack of
• 14:43
  Speaker 1: papers to be bound and shipped are ancient history.
• 14:46
  Speaker 2: They have to be integrated from the very beginning of
• 14:49
  Speaker 2: the operating model. The source highlights some really cutting edge
• 14:52
  Speaker 2: context for where we are in 2026. We aren't just
• 14:56
  Speaker 2: managing flat documents anymore. We are managing highly structured data points.
• 15:00
  Speaker 1: Regulatory information is becoming entirely metadata driven. Exactly. The source
• 15:05
  Speaker 1: specifically mentions the EMA's SBR framework in Europe. For the
• 15:09
  Speaker 1: listener who hasn't encountered this, think of SBRR as like
• 15:13
  Speaker 1: a universal barcode system for every single ingredient and organization
• 15:18
  Speaker 1: involved in making a drug.
• 15:19
  Speaker 2: That's a great way to put it.
• 15:21
  Speaker 1: Because before this, France might call an active ingredient one
• 15:23
  Speaker 1: thing and Germany might call it another. creating a total
• 15:26
  Speaker 1: regulatory nightmare. SBIR forces everyone to seek the exact same
• 15:30
  Speaker 1: data language.
• 15:31
  Speaker 2: It really does. SBIR stands for Substance, Product, Organization, and
• 15:36
  Speaker 2: Referential Master Data. The EMA is aggressively implementing ISO-IDMP, which
• 15:42
  Speaker 2: is the international standard for the identification of medicinal products.
• 15:45
  Speaker 1: So they're standardizing the actual data elements that make up
• 15:48
  Speaker 1: a regulatory submission.
• 15:49
  Speaker 2: Yes. And the EMA's 2026-2028 Network Beta Steering Group Work
• 15:52
  Speaker 2: Plan heavily emphasizes this move toward high-quality, interoperable regulatory master beta.
• 16:01
  Speaker 1: And the new ECPD version 4.0 plays right into this,
• 16:04
  Speaker 1: doesn't it? The source notes the June 2026 endorsement of
• 16:07
  Speaker 1: the ICH Implementation Guide version 1.7.
• 16:10
  Speaker 2: It does. We are moving away from submitting PDFs towards
• 16:13
  Speaker 2: submitting structured data that machines can actually read and cross-reference.
• 16:16
  Speaker 1: Which is huge. It is.
• 16:18
  Speaker 2: And this is why Regulatory Information Management, or RIM, is
• 16:21
  Speaker 2: the absolute central nervous system of a global operation today.
• 16:25
  Speaker 1: So a good RIM system ensures that when a local
• 16:27
  Speaker 1: affiliate in Australia updates an approval status, the global supply
• 16:31
  Speaker 1: chain team in Switzerland sees it instantly.
• 16:33
  Speaker 2: Exactly. It creates a single source of truth across all
• 16:35
  Speaker 2: those organizational layers we just talked about.
• 16:38
  Speaker 1: But, you know, this brings up the elephant in the room.
• 16:40
  Speaker 1: If we are moving toward a world of hyper-structured data, metadata,
• 16:44
  Speaker 1: and standardized vocabularies, we have to talk about artificial intelligence.
• 16:48
  Speaker 1: We do. So what does this all mean for the
• 16:50
  Speaker 1: human workers? If a machine can read every global regulation instantly,
• 16:56
  Speaker 1: summarize it, and map it to our internal data, is
• 16:59
  Speaker 1: AI just going to automate these local intelligence nodes out
• 17:02
  Speaker 1: of a job? Like, do we still need a regulatory
• 17:05
  Speaker 1: team in every country?
• 17:06
  Speaker 2: It is the question every executive is asking right now.
• 17:09
  Speaker 2: But the answer, surprisingly, is that AI does not remove
• 17:13
  Speaker 2: the need for human regulatory professionals.
• 17:15
  Speaker 1: Really?
• 17:16
  Speaker 2: Yeah. What it does is dramatically shift where they add value.
• 17:20
  Speaker 1: How so? Because AI is getting awfully good at reading
• 17:22
  Speaker 1: bureaucratic text.
• 17:23
  Speaker 2: It is very good at it. But look at the
• 17:24
  Speaker 2: January 2026 Joint Guiding Principles for Good AI Practice in
• 17:28
  Speaker 2: Drug Development, published by the FDA and the EMA.
• 17:31
  Speaker 1: OK, what do they say?
• 17:32
  Speaker 2: They heavily emphasize human-centric design, multidisciplinary expertise, and clear contexts
• 17:38
  Speaker 2: of use. AI-assisted systems are incredible at the heavy lifting
• 17:43
  Speaker 2: monitoring regulatory sources, summarizing massive legislative changes, comparing requirements across borders.
• 17:50
  Speaker 1: AI is gathering the raw information and connecting the basic dots.
• 17:54
  Speaker 2: Right. And flagging which of your products might be affected
• 17:57
  Speaker 2: by a new rule. And this is a critical distinction.
• 18:01
  Speaker 2: A generated interpretation of a national regulatory requirement is not
• 18:05
  Speaker 2: a validated local position.
• 18:07
  Speaker 1: Ah, I see. Yeah. So just because an AI model
• 18:09
  Speaker 1: tells you what a French regulation theoretically says, it doesn't
• 18:13
  Speaker 1: mean the actual humans at the French Health Authority understand.
• 18:15
  Speaker 1: will agree with that interpretation in the highly specific context
• 18:19
  Speaker 1: of your new oncology drug.
• 18:21
  Speaker 2: You hit the nail on the head. And this leads
• 18:22
  Speaker 2: to this beautiful irony outlined in the text. As automated
• 18:25
  Speaker 2: systems make global information easier and faster to access, local
• 18:29
  Speaker 2: regulatory affairs actually becomes more important, not less.
• 18:32
  Speaker 1: Because they become the ultimate validators and context owners.
• 18:35
  Speaker 2: Precisely. Their role elevates. They shift from just being an
• 18:39
  Speaker 2: information gateway, someone who manually reads guidelines and reports back
• 18:43
  Speaker 2: to headquarters, To being the owner of contextual interpretation.
• 18:47
  Speaker 1: Because they actually talk to the people enforcing the rules. Right.
• 18:51
  Speaker 2: They validate the precedence. They understand the implementation reality on
• 18:54
  Speaker 2: the ground that the AI, by definition, cannot see because
• 18:58
  Speaker 2: it isn't written down in the training data.
• 19:00
  Speaker 1: And there's another catch to this tech utopia, isn't there?
• 19:03
  Speaker 1: AI demands impeccable data. It's the classic garbage-in, garbage-out scenario.
• 19:09
  Speaker 2: It is the ultimate garbage-in, garbage-out scenario. AI cannot magically
• 19:13
  Speaker 2: fix a sloppy RIM system.
• 19:15
  Speaker 1: Right.
• 19:16
  Speaker 2: It cannot automatically repair ambiguous ownership or inconsistent regulatory classifications
• 19:20
  Speaker 2: from five years ago. If your underlying data governance is weak,
• 19:24
  Speaker 2: AI will just help you make the wrong decisions much,
• 19:26
  Speaker 2: much faster.
• 19:27
  Speaker 1: So strong data governance is an absolute prerequisite for any
• 19:31
  Speaker 1: of this 2026 technology to work.
• 19:33
  Speaker 2: 100%.
• 19:34
  Speaker 1: Okay. So if we pull all of this together, the
• 19:36
  Speaker 1: ultimate takeaway of this DDReG five-layer model is incredibly clear.
• 19:42
  Speaker 1: Strategy is global, coordination is regional, execution is local, and
• 19:47
  Speaker 1: regulatory information is universally shared.
• 19:50
  Speaker 2: That sums it up perfectly.
• 19:51
  Speaker 1: The best global regulatory organization isn't the one with the
• 19:55
  Speaker 1: tightest fist of centralized control. It's the one that assigns
• 19:58
  Speaker 1: the right decision rights to the right layer, trusting the
• 20:02
  Speaker 1: local experts while never losing that overarching global visibility.
• 20:07
  Speaker 2: It is about putting each regulatory decision in the hands
• 20:09
  Speaker 2: of the team best equipped to make it and giving
• 20:12
  Speaker 2: them the technological infrastructure, that central nervous system, to communicate
• 20:16
  Speaker 2: that decision instantly across the entire enterprise.
• 20:19
  Speaker 1: It really makes you look at those whiteboard organizational charts
• 20:21
  Speaker 1: entirely differently. They can't just be static boxes. They have
• 20:25
  Speaker 1: to be living, breathing networks of communication.
• 20:28
  Speaker 2: Exactly. They have to adapt to reality.
• 20:30
  Speaker 1: But I want to leave you, our listener, with a
• 20:32
  Speaker 1: final thought to ponder today that really builds on all
• 20:35
  Speaker 1: this source material. We know that AI requires pristine structured
• 20:39
  Speaker 1: data to work properly across this complex five-layer model. But
• 20:44
  Speaker 1: think about this. If AI instantly synthesizes global regulatory intelligence
• 20:49
  Speaker 1: but relies entirely on human validation, what happens to a
• 20:53
  Speaker 1: multi-billion dollar global rollout if just one local affiliate misinterprets
• 20:58
  Speaker 1: a nuance and feeds that bad context back into the
• 21:01
  Speaker 1: central AI? Oh, wow. Right. As our tools get smarter
• 21:04
  Speaker 1: and faster, does the margin for human error actually shrink?
• 21:07
  Speaker 1: Or does the impact of a single human error simply
• 21:09
  Speaker 1: become vastly amplified?
• 21:11
  Speaker 2: A fascinating and slightly terrifying thought to end on.
• 21:14
  Speaker 1: Indeed. Thank you so much for joining us on this
• 21:16
  Speaker 1: deep dive into the hidden machinery of global pharmaceutical regulation.
• 21:19
  Speaker 1: Keep asking questions. Keep challenging those perfect whiteboard models. And
• 21:23
  Speaker 1: keep digging deeper into the systems that shape our world.
• 21:26
  Speaker 1: We'll catch you next time.